HC Wainwright has reaffirmed its "Neutral" rating for Evommune (NYSE:EVMN), while the broader analyst consensus remains a "Moderate Buy" with an average price target of $41.56. Despite shares opening higher, the clinical-stage biotech missed its recent quarterly earnings estimates, reporting a loss of $0.89 per share against an expected $0.68 loss. Insider selling amounting to $655,000 occurred in the last quarter, yet institutional investors like Janus Henderson and Perceptive Advisors have built significant positions in the company.

HP has announced a collaboration with Red Hat and NVIDIA to extend its data-center AI architecture to the edge. This initiative aims to provide an open, enterprise-grade AI platform that enables organizations to deploy and manage AI workloads closer to users, applications, machines, and data. The solution will combine HP ZGX Fury, powered by the NVIDIA GB300 Grace Blackwell Ultra Desktop Superchip, and Red Hat AI Factory with NVIDIA, offering enhanced AI and orchestration capabilities for various industries.

KeyCorp (NYSE:KEY) is under scrutiny as US markets reopen, with its performance heavily influenced by broader financial themes such as funding costs, credit conditions, deposit competition, capital markets, and interest-rate sensitivity. Despite these macro factors, the article emphasizes that company-specific execution in its commercial and consumer banking across a broad regional footprint remains crucial for its success. The report suggests that investors should focus on KeyCorp's operating model, customer base, competitive position, and capital needs to assess its trajectory.

Northern Trust (NASDAQ:NTRS) is in focus as U.S. markets reopen after Labor Day, with attention on financial stocks due to firm rate expectations and stronger labor data. The company's core business revolves around asset servicing, wealth management, and institutional financial services. Key themes for NTRS and the broader financial sector include credit conditions, deposit competition, capital markets, and interest-rate sensitivity.

This article summarizes major analyst calls made on Wednesday, September 9, 2026. Key recommendations include upgrades for companies like Sagimet Biosciences, Lithium Americas, and Sasol, and new "buy" ratings for Faeth Therapeutics, Kodiak AI, Pasqal, Affirm, Robinhood, Chime, Dave, Quanta Services, First Solar, Liberty Formula One, Aptiv, Abercrombie & Fitch, Pursuit Attractions & Hospitality, Atkis Oncology, Teva Pharmaceuticals, and Bausch + Lomb. It also highlights reiterations for Dell, Nvidia, and Tesla, and an upgrade for Martin Marietta.

AGAT Software has been recognized as an Example Vendor in the 2026 Gartner Market Overview for AI Usage Control, highlighting its role in the emerging cybersecurity market for managing third-party and homegrown AI applications. The company's platform, Pragatix, provides visibility and control over enterprise AI usage, including autonomous agents, to address growing security gaps and policy enforcement needs. This recognition positions AGAT Software among global cybersecurity companies as AI usage becomes more complex and agentic.

Analog Devices (ADI) is set to acquire Alif Semiconductor in an all-cash deal valued at $1.35 billion. This acquisition highlights Analog Devices' strategic move to expand its portfolio. The news comes amidst other analyst activities concerning Analog Devices, including price target adjustments and upgrades.

KeyCorp has announced the appointment of Chris Doll as its new chief strategy officer and deputy chief financial officer. Doll, who previously served as EVP and CFO of City National Bank, will report to Clark Khayat, KeyCorp's CFO and head of technology. This strategic hire aims to leverage Doll's financial expertise and leadership to drive KeyCorp's growth and enhance value for stakeholders.

The Cooper Companies (COO) is set to announce its fiscal third-quarter 2026 results, with sales expected to reach $1.1 billion and EPS at $1.11 per share. Despite a strong earnings surprise history, the Zacks Model does not conclusively predict an earnings beat this quarter due to a 0.00% Earnings ESP and a Zacks Rank #4 (Sell). Performance is anticipated to be driven by its CooperVision business, improving fertility trends in CooperSurgical, and operational efficiencies, although macroeconomic headwinds in Asia Pacific and foreign exchange rates may pose challenges.

European lawmakers have denied Booking Holdings' appeal regarding its acquisition of Etraveli Group, upholding the European Commission's decision that the deal would boost Booking's dominant position and increase barriers to entry. The online travel giant initially announced the €1.6 billion acquisition in late 2021, but the EC barred it three years ago, leading to Booking's unsuccessful appeal. Booking Holdings stated disagreement with the outcome and is considering an appeal to the European Court of Justice.